Trump announced a decisive measure that could sever an entire sector's future in the EU.
For European pharmaceutical manufacturers, a critical period has begun, as Donald Trump plans to impose significant tariffs on generic drugs after a two-year grace period. The EU export is expected to increase, but manufacturers must make quick decisions about whether to build factories in the United States or remain on the continent. Billions of dollars in investment and the future of the pharmaceutical industry depend on these decisions in the coming years.
The clock is ticking for European pharmaceutical manufacturers: Donald Trump has given two years of grace, but will then impose 100 and 200 percent tariffs on generic drugs. While the grace period will likely bring significant growth to EU exports, European companies must soon decide whether to build factories in the United States or continue their investments on the continent. In the coming years, billions of euros could be invested, and the fate of an entire sector could depend on what can be considered a viable strategy in such a situation.
Related Reading
Energy crisis: record heat, slightly higher Danube, drying streams and ongoing energy and water conservation nationwide
Magyar Péter made an important announcement: there is no need for voluntary consumption reduction.
